Study S002054

SeMaglutide and Albuminuria Reduction Trial in Obese Individuals Without Diabetes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT04889183
Acronym: SMART
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 125
Start: 2022-03-14
Primary completion: 2024-05-28
Lead sponsor: University Medical Center Groningen
Conditions: Obesity; Albuminuria
Interventions: DRUG:Semaglutide; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: UNDECIDED
Secondary identifiers: EUDRACT_NUMBER:2021-001247-27

Registered primary outcomes

Change from baseline to week 24 in urinary albumin:creatinine ratio (UACR) [Week 1 to week 24]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0004549	Effects of Semaglutide on Body Composition and GFR: A Prespecified Analysis of the SMART Trial. Heerspink HJL, Clinical journal of the American Society of Nephrology : CJASN	2026	Randomized trial	PMID 42308057 DOI	cites ClinicalTrials.gov:NCT04889183; registry reference DERIVED:42308057
R0018719	Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial. Apperloo EM, Nature medicine	2025	Randomized trial	PMID 39455729 DOI	cites ClinicalTrials.gov:NCT04889183; registry reference DERIVED:39455729